Cortland Associates Inc. MO Has $325,000 Stake in Johnson & Johnson (NYSE:JNJ)

Cortland Associates Inc. MO raised its stake in Johnson & Johnson (NYSE:JNJ) by 21.2% during the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 2,008 shares of the company’s stock after buying an additional 351 shares during the quarter. Cortland Associates Inc. MO’s holdings in Johnson & Johnson were worth $325,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds also recently modified their holdings of the business. Donaldson Capital Management LLC raised its position in shares of Johnson & Johnson by 2.1% during the third quarter. Donaldson Capital Management LLC now owns 343,944 shares of the company’s stock worth $55,740,000 after purchasing an additional 7,092 shares during the period. Robeco Institutional Asset Management B.V. raised its position in Johnson & Johnson by 2.6% in the 3rd quarter. Robeco Institutional Asset Management B.V. now owns 1,390,984 shares of the company’s stock valued at $225,423,000 after buying an additional 35,717 shares during the last quarter. Lansing Street Advisors raised its position in Johnson & Johnson by 1.8% in the 3rd quarter. Lansing Street Advisors now owns 5,607 shares of the company’s stock valued at $909,000 after buying an additional 101 shares during the last quarter. BSW Wealth Partners raised its position in Johnson & Johnson by 2.2% in the 3rd quarter. BSW Wealth Partners now owns 6,738 shares of the company’s stock valued at $1,092,000 after buying an additional 143 shares during the last quarter. Finally, Angeles Wealth Management LLC raised its position in Johnson & Johnson by 22.2% in the 3rd quarter. Angeles Wealth Management LLC now owns 15,837 shares of the company’s stock valued at $2,567,000 after buying an additional 2,877 shares during the last quarter. Institutional investors and hedge funds own 69.55% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of research firms have weighed in on JNJ. Cantor Fitzgerald restated an “overweight” rating and issued a $215.00 price target on shares of Johnson & Johnson in a research note on Wednesday, October 16th. Daiwa Capital Markets downgraded Johnson & Johnson from an “outperform” rating to a “neutral” rating and decreased their price target for the company from $160.00 to $150.00 in a research note on Tuesday, July 23rd. Sanford C. Bernstein raised their price target on Johnson & Johnson from $161.00 to $171.00 in a research note on Thursday, July 18th. Daiwa America downgraded Johnson & Johnson from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, July 23rd. Finally, TD Securities decreased their price target on Johnson & Johnson from $195.00 to $185.00 in a research note on Thursday, July 18th. Six equities research analysts have rated the stock with a hold rating, seven have given a buy rating and one has assigned a strong buy rating to the company’s stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $175.93.

Johnson & Johnson Stock Performance

JNJ opened at $158.24 on Tuesday. The business has a fifty day simple moving average of $163.18 and a 200 day simple moving average of $155.68. The company has a market capitalization of $380.98 billion, a PE ratio of 22.90, a price-to-earnings-growth ratio of 2.84 and a beta of 0.52. Johnson & Johnson has a 1 year low of $143.13 and a 1 year high of $168.85. The company has a debt-to-equity ratio of 0.45, a current ratio of 1.03 and a quick ratio of 0.79.

Johnson & Johnson (NYSE:JNJ) last released its quarterly earnings results on Tuesday, October 15th. The company reported $2.42 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.21 by $0.21. The business had revenue of $22.47 billion during the quarter, compared to the consensus estimate of $22.17 billion. Johnson & Johnson had a return on equity of 35.45% and a net margin of 19.14%. The firm’s quarterly revenue was up 5.2% on a year-over-year basis. During the same period in the previous year, the company posted $2.66 EPS. Research analysts expect that Johnson & Johnson will post 9.94 EPS for the current year.

Johnson & Johnson Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, December 10th. Shareholders of record on Tuesday, November 26th will be issued a $1.24 dividend. The ex-dividend date of this dividend is Tuesday, November 26th. This represents a $4.96 annualized dividend and a yield of 3.13%. Johnson & Johnson’s dividend payout ratio is presently 71.78%.

Insider Buying and Selling at Johnson & Johnson

In other Johnson & Johnson news, VP Robert J. Decker sold 5,635 shares of Johnson & Johnson stock in a transaction on Friday, August 30th. The stock was sold at an average price of $165.06, for a total value of $930,113.10. Following the completion of the transaction, the vice president now directly owns 18,973 shares of the company’s stock, valued at $3,131,683.38. The trade was a 0.00 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Insiders own 0.16% of the company’s stock.

Johnson & Johnson Company Profile

Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizophrenia; oncology, such as prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; cardiovascular and metabolism, including thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use.